Core Insights - Theravance Biopharma will present new analyses on YUPELRI at the CHEST 2025 annual meeting, highlighting its effectiveness in reducing exacerbations in COPD patients [1][2] Company Overview - Theravance Biopharma focuses on delivering impactful medicines, with YUPELRI (revefenacin) approved for the maintenance treatment of COPD [3] - The company is also developing Ampreloxetine, a potential first-in-class therapy for neurogenic orthostatic hypotension in patients with Multiple System Atrophy [3] Research Findings - A retrospective analysis showed that patients adherent to YUPELRI had significantly fewer exacerbations and lower healthcare costs compared to non-adherent patients [2][6] - Post-hoc analyses from a Phase 3 safety study indicated that YUPELRI's exacerbation profile over one year is at least as effective as tiotropium [2][6] Presentation Details - The presentations at CHEST 2025 include: - "Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study" by Edmund J Moran, Ph.D. on October 21, 2025 [2] - "Adherence to Revefenacin Associated with Reductions in Exacerbations and Healthcare Costs Following a COPD-Related Hospitalization" by Grace Leung, MPH on October 21, 2025 [2]